novo nordisk semaglutide patent Ozempic's problem: how lost control of a blockbuster drug. ๐ Demand for GLP-1 weight-loss drugs has exploded, turning Ozempic into a $40bn+ revenue engine for Novo Nordisk. But, despite Novo's Ozempic Patent Expires Jan.
Pay in 4 interest-free payments of $5.06 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Jul 31 - Aug 5




)






















